Green Inhaler Innovation Driven by Environmental and Regulatory Pressure

Inhaler market was valued at $36.2 billion in 2024 and is projected to reach $71.4 billion by 2035, growing at a CAGR of 5.9% during the forecast period (2025–2035). The shift to eco-friendly inhalers is being pushed by increased environmental concerns and regulatory pressure to minimize the use of high global warming potential (GWP) propellants usually found in standard metered-dose inhalers (MDIs).  These inhalers considerably increase healthcare-related carbon emissions.  In response, Kindeva, AstraZeneca, and GSK are developing inhalers using low-GWP or propellant-free technologies.

Browse the full report description of “Inhaler Market Size, Share & Trends Analysis Report by Type (Metered-dose, Dry powder, and Soft mist inhalers), by Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and Others), and by Distribution Channel (Online and Offline), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/inhaler-market

In October 2023, the EU obtained a provisional agreement to gradually phase out all F-gases by 2050. EU F-gas legislation aims to reduce the use of high-GWP propellants in pressurized metered-dose inhalers (pMDIs) as it contributes to climate change. Under this regulation, inhaler manufacturers are encouraged to switch to low-GWP propellants (like HFO-1234ze). This supports the EU’s climate goals by reducing greenhouse gas emissions from medical products. 

For instance, in May 2024, Kindeva Drug Delivery, a global leader in drug-device combination products, announced its investment in a second manufacturing line at its Loughborough, UK facility. This new line will support the production of pressurized metered-dose inhalers (pMDIs) formulated with low global warming potential (GWP) propellants, reinforcing the company’s commitment to sustainable pharmaceutical solutions.  This new line will be capable of handling both HFA-152a and HFO-1234ze propellants that have a GWP of 90% and 99.9% lower than the industry standard HFA-134a, respectively, and is anticipated to be operational in 2026.

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Type 

o By Disease Indication 

o By Distribution Channel

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - GlaxoSmithKline PLC, Cipla Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., among others. 

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Inhaler Market Report Segment

By Type

• Metered-dose
• Dry powder
• Soft mist inhalers

By Disease Indication

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Others (Pulmonary Arterial Hypertension (PAH), Non-Respiratory Conditions)

By Distribution Channel

• Offline 
• Online

Global Inhaler Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/inhaler-market